<DOC>
	<DOCNO>NCT01310478</DOCNO>
	<brief_summary>To investigate safety tolerance dose-escalation infusional recombinant human endostatin combination mFOLFOX6 initial therapy patient metastatic colorectal cancer .</brief_summary>
	<brief_title>Recombinant Human Endostatin Combination With mFOLFOX6 Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description>Recombinant human endostatin ( Endostar ) commonly use intermittent intravenous adminstration routine clinical practice China . It difficult maintain steady-state plasma concentration agent due manner application . Continous infusional Endostar design alter imblance concentration avoid compromise efficacy anti-angionesis therapy.The strategy dose-escalation use study order obtain optimal dosage Endostar next phase Ⅱ trial .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Endostatins</mesh_term>
	<criteria>1 . Provision write informed consent 2 . Histological cytological confirm adenocarcinoma colon rectum 3 . Age 18 70 year . 4 . Patients must receive prior systemic therapy metastatic disease . Anyadjuvant/neoadjuvant oxaliplatin therapy must receive &gt; 12 month prior study entry adjuvant/neoadjuvant 5FU must receive &gt; 6 month prior study entry . Patients previously disease free follow neoadjuvant chemotherapy regimen resection primary tumour metastatic disease eligible.. 5 . ECOG Performance Status 0 or1 6 . Life expectancy least 12 week 7 . The required evidence measurable lesion least 10 mm long diameter spiral compute tomography scan 20 mm conventional technique ( RECIST criterion ) 8 . Adequate bone marrow , liver renal function assess follow laboratory requirement conduct within 7 day prior screen : Hemoglobin &gt; 9.0 g/dl Absolute neutrophil count ( ANC ) &gt; 1,500/mm3 Platelet count 100,000/μl Total bilirubin &lt; 1.5 time upper limit normal ALT AST &lt; 2.5 x ULN ( &lt; 5 x ULN patient liver involvement cancer ) ALP &lt; 4 x ULN PTINR/PTT &lt; 1.5 x upper limit normal Serum creatinine &lt; 1.5 x ULN 1 . History cardiac disease : congestive heart failure &gt; NYHA class 2 history symptomatic coronary artery disease ( include angina myocardial infarction ) ischemic heart disease cardiac arrhythmia require antiarrhythmic therapy ( beta blocker digoxin permit ) uncontrolled hypertension 2 . History HIV infection chronic hepatitis B C ( high copy number HBV ) . 3 . Active clinically serious infection ( &gt; grade 2 NCICTC version 3.0 ) 4 . Symptomatic metastatic brain meningeal tumor ( unless patient &gt; 6 month definitive therapy , negative imaging study within 4 week study entry clinically stable respect tumor time study entry ) 5 . Patients seizure disorder require medication ( steroids antiepileptic ) 6 . Previous concurrent cancer distinct primary site histology cancer evaluate study EXCEPT cervical carcinoma situ , treat basal cell carcinoma within 5 year . 7 . Recent ( &lt; 28 day ) major thoracic abdominal surgery prior entry studyor surgical incision fully heal 8 . Known hypersensitivity recombinant human endostatin , oxaliplatin , 5FU , leucovorin , capecitabine excipients product 9 . Substance abuse , medical , psychological social condition may interfere patient 's participation study evaluation study result . 10 . Peripheral neuropathy ≥CTC grade 2 11 . Any condition unstable could jeopardize safety patient compliance study 12 . Pregnant breastfeeding patient . Women childbearing potential must negative pregnancy test perform within 7 day start treatment . Both men woman enrol trial must use adequate barrier birth control measure course trial ( men least 3 month last administration study medication ) .</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Recombinant human endostatin</keyword>
	<keyword>Metastatic colorectal cancer</keyword>
	<keyword>DLT</keyword>
	<keyword>MTD</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>